Trial Profile
A randomized phase II study of daily administrations versus alternate-day administrations of TS-1 for the elderly patient with completely resected pathological stage IA(T1bN0M0)-IIIA of non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Oct 2022 Status changed from active, no longer recruiting to completed.
- 15 Oct 2020 Planned End Date changed from 30 Apr 2021 to 30 Jun 2022.
- 30 Dec 2016 Status changed from recruiting to active, no longer recruiting.